Drug Profile
BNT 162a1
Alternative Names: BNT-162a1Latest Information Update: 09 May 2023
Price :
$50
*
At a glance
- Originator BioNTech
- Developer BioNTech; Pfizer; Shanghai Fosun Pharmaceutical
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections